A new therapy is offering hope to Parkinson's patients in Japan. They will soon be able to receive the world's first treatment using lab-grown cells under the country's public health insurance.

全新疗法为日本帕金森病患者带来了新希望。 患者很快就能接受全球首例实验室培育细胞疗法，且该治疗将纳入日本公共医疗保险报销范围。

Amchepry is produced by Japanese drugmaker Sumitomo Pharma. It uses neural tissue derived from induced pluripotent stem cells, or iPS cells.

这款疗法名为Amchepry，由日本住友制药研发生产。 它采用诱导多能干细胞（iPS细胞）分化培育而成的神经组织开展治疗。

The therapy is designed to restore motor function in people with Parkinson's disease. Seven patients have taken part in clinical tests, and some showed improvements in their motor skills.

该疗法旨在帮助帕金森病患者恢复运动机能。 目前已有七名患者参与临床试验，部分患者的运动能力已出现明显改善。

Medical authorities have decided to cover Amchepry under public health insurance. They have set the cost of a single treatment at around 350,000 dollars.

日本医疗主管部门已决定将Amchepry纳入公共医保体系。 单次治疗定价约35万美元。

The burden on patients will be sharply reduced, thanks to a system that caps monthly out-of-pocket medical expenses.

依托日本高额医疗费封顶报销制度，患者个人承担的费用将大幅降低。

Sumitomo Pharma expects treatment to begin around this fall. It projects about 130 patients a year will undergo treatment by fiscal 2035.

住友制药预计，今年秋季前后正式开展临床治疗。 预估到2035财年，每年约有130名患者接受该项治疗。

Meanwhile, the health ministry has given conditional approval for the production and sale of ReHeart, an iPS therapy for severe heart failure. The government will discuss whether to cover it under public health insurance as well.

与此同时，日本厚生劳动省已有条件批准重症心力衰竭iPS细胞疗法ReHeart的生产与上市。 后续政府还将研讨这款疗法是否同样纳入公共医疗保险。

素材来源：iYuba

本文来自公众微信号：英语阅读EnglishDaily